Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF)

You'll hear about Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF).

Kalydeco (ivacaftor) is the first drug that treats the underlying genetic mutation that causes CF...not just its symptoms.

Unfortunately, it'll only help patients with a rare mutation that affects about 4% of CF patients...about 1200 people in the U.S.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote